metformin has been researched along with Rectal Neoplasms in 20 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin use was associated with better tumor responses and cancer-specific survival, as well as a lower risk of cancer recurrence, in patients with diabetes mellitus who had lymph node downstaging after neoadjuvant concurrent chemoradiotherapy in rectal cancer." | 3.96 | Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer. ( Cheon, JH; Kim, JM; Kim, TI; Kim, WH; Lee, JH; Park, JW; Park, SJ; Park, YH, 2020) |
| "For patients with rectal cancer and treated with neoadjuvant chemoradiotherapy, metformin administration in diabetic patients increased the pathological response on tumor-regression grade and T downstaging." | 3.01 | Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. ( Chern, YJ; Hsu, YJ; Lai, IL; Tsai, WS; Wu, MY; You, JF, 2023) |
| "Metformin has been reported to be associated with improved cancer prognosis when used in combination with chemotherapy and/or radiotherapy." | 2.82 | Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. ( Kitagawa, Y; Matsui, S; Okabayashi, K; Sakamoto, K; Seishima, R; Shigeta, K, 2022) |
| "An otherwise untreated rectal cancer, progressing over 3 years, regressed after severe toxic dermatitis lasting over one week." | 2.72 | Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature. ( Bukovsky, A, 2021) |
| "Metformin has been demonstrated to reduce cell-viability post-radiotherapy in both rectal and prostate cancer cell lines, with an enhanced effect in tumours with a p53 mutation and increased apoptosis post-radiotherapy for cervical cancer." | 2.72 | Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature. ( Clifford, RE; Fok, M; Gerrard, AD; Vimalachandran, D, 2021) |
| "The management of locally advanced rectal cancer has passed a long way of developments, where total mesorectal excision and preoperative radiotherapy are crucial to secure clinical outcome." | 2.58 | Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer. ( Aerts, J; de Mey, S; De Ridder, M; Dufait, I; Engels, B; Feron, O; Gevaert, T; Jiang, H; Verovski, V; Wang, H, 2018) |
| "Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients." | 2.55 | Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. ( Chambers, AC; Cotton, DE; Gash, KJ; Thomas, MG; Williams, AC, 2017) |
| "In patients with rectal cancer who underwent preoperative CCRT, neoadjuvant therapy of metformin before CCRT was significantly associated with good tumor response." | 1.72 | Neoadjuvant therapy of metformin is associated with good tumor response after preoperative concurrent chemoradiotherapy for rectal cancer. ( Han, J; Han, SH; Kim, H; Kim, JH; Lee, JW, 2022) |
| "Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design." | 1.72 | The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study. ( Arffman, M; Erkinantti, S; Hautakoski, A; Jukkola, A; Karihtala, P; Läärä, E; Puistola, U; Sund, R; Urpilainen, E, 2022) |
| "Metformin was not associated with better tumor responses or survival after neoadjuvant treatment." | 1.62 | Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer? ( Codina-Cazador, A; Cornejo, L; Farrés, R; Hernández-Yagüe, X; Maldonado, E; Planellas, P; Rodríguez-Hermosa, JI; Timoteo, A, 2021) |
| "Metformin is an attractive alternative radiosensitizing agent to be considered in future studies/trials." | 1.56 | Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer. ( Asprino, PF; Camargo, AA; Costa, ÉT; Fernandes, JM; Jandrey, EHF; Koyama, FC; Leite, KRM; Perez, RO, 2020) |
| "Metformin treatment did not influence any of the outcomes." | 1.51 | Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer. ( Fransgaard, T; Gögenur, I; Hallas, J; Thygesen, LC, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | 1.51 | Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "However, the effects of metformin in rectal cancer are controversial." | 1.46 | Association between Metformin Use and Survival in Nonmetastatic Rectal Cancer Treated with a Curative Resection: A Nationwide Population Study. ( Choi, JA; Ki, YJ; Kim, HJ; Kim, MS; Ko, MJ; Moon, SM; Park, CM; Seo, YS, 2017) |
| "A total of 543 rectal cancer patients who were treated with neoadjuvant chemoradiotherapy followed by radical surgery from January 2007 to December 2011 were reviewed." | 1.43 | Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. ( Cho, YB; Choi, DH; Huh, JW; Kim, HC; Lee, WY; Oh, BY; Park, HC; Park, YA; Park, YS; Yun, SH, 2016) |
| "Metformin use was significantly associated with pCR rate on univariate (P = 0." | 1.39 | Metformin use and improved response to therapy in rectal cancer. ( Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kelly, P; Krishnan, S; Rodriguez-Bigas, MA; Sandulache, VC; Skibber, JM; Skinner, HD, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 12 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J | 1 |
| Kim, JH | 1 |
| Lee, JW | 1 |
| Han, SH | 1 |
| Kim, H | 2 |
| Tojo, M | 1 |
| Miyato, H | 1 |
| Koinuma, K | 1 |
| Horie, H | 1 |
| Tsukui, H | 1 |
| Kimura, Y | 1 |
| Kaneko, Y | 1 |
| Ohzawa, H | 1 |
| Yamaguchi, H | 1 |
| Yoshimura, K | 1 |
| Lefor, AK | 1 |
| Sata, N | 1 |
| Kitayama, J | 1 |
| Sakamoto, K | 1 |
| Okabayashi, K | 1 |
| Matsui, S | 1 |
| Seishima, R | 1 |
| Shigeta, K | 1 |
| Kitagawa, Y | 1 |
| Erkinantti, S | 1 |
| Hautakoski, A | 1 |
| Sund, R | 1 |
| Arffman, M | 1 |
| Urpilainen, E | 1 |
| Puistola, U | 1 |
| Läärä, E | 1 |
| Jukkola, A | 1 |
| Karihtala, P | 1 |
| Georgopoulos, NS | 1 |
| Tolia, M | 1 |
| Mauri, D | 1 |
| Kamposioras, K | 1 |
| Charalampakis, N | 1 |
| Tsoukalas, N | 1 |
| Gkantaifi, A | 1 |
| Lai, IL | 1 |
| You, JF | 1 |
| Tsai, WS | 1 |
| Hsu, YJ | 1 |
| Chern, YJ | 1 |
| Wu, MY | 1 |
| Fernandes, JM | 1 |
| Jandrey, EHF | 1 |
| Koyama, FC | 1 |
| Leite, KRM | 1 |
| Camargo, AA | 1 |
| Costa, ÉT | 1 |
| Perez, RO | 2 |
| Asprino, PF | 1 |
| Fernandez, LM | 1 |
| Ortega, CD | 1 |
| Kim, JM | 1 |
| Park, JW | 1 |
| Lee, JH | 1 |
| Park, YH | 1 |
| Park, SJ | 1 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Kim, TI | 1 |
| Bukovsky, A | 1 |
| Clifford, RE | 1 |
| Gerrard, AD | 1 |
| Fok, M | 1 |
| Vimalachandran, D | 1 |
| Planellas, P | 1 |
| Cornejo, L | 1 |
| Rodríguez-Hermosa, JI | 1 |
| Maldonado, E | 1 |
| Timoteo, A | 1 |
| Hernández-Yagüe, X | 1 |
| Farrés, R | 1 |
| Codina-Cazador, A | 1 |
| Gash, KJ | 1 |
| Chambers, AC | 1 |
| Cotton, DE | 1 |
| Williams, AC | 1 |
| Thomas, MG | 1 |
| de Mey, S | 1 |
| Jiang, H | 1 |
| Wang, H | 1 |
| Engels, B | 1 |
| Gevaert, T | 1 |
| Dufait, I | 1 |
| Feron, O | 1 |
| Aerts, J | 1 |
| Verovski, V | 1 |
| De Ridder, M | 1 |
| Fransgaard, T | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Gögenur, I | 1 |
| Besic, N | 1 |
| Povsic, MK | 1 |
| Park, JH | 1 |
| Kim, YH | 1 |
| Park, EH | 1 |
| Lee, SJ | 2 |
| Kim, A | 1 |
| Lee, SB | 1 |
| Shim, S | 1 |
| Jang, H | 1 |
| Myung, JK | 1 |
| Park, S | 1 |
| Kim, MJ | 1 |
| Skinner, HD | 1 |
| Crane, CH | 1 |
| Garrett, CR | 1 |
| Eng, C | 1 |
| Chang, GJ | 1 |
| Skibber, JM | 1 |
| Rodriguez-Bigas, MA | 1 |
| Kelly, P | 1 |
| Sandulache, VC | 1 |
| Delclos, ME | 1 |
| Krishnan, S | 1 |
| Das, P | 1 |
| Oh, BY | 1 |
| Park, YA | 1 |
| Huh, JW | 1 |
| Cho, YB | 1 |
| Yun, SH | 1 |
| Lee, WY | 1 |
| Park, HC | 1 |
| Choi, DH | 1 |
| Park, YS | 1 |
| Kim, HC | 1 |
| Ki, YJ | 1 |
| Kim, HJ | 1 |
| Kim, MS | 1 |
| Park, CM | 1 |
| Ko, MJ | 1 |
| Seo, YS | 1 |
| Moon, SM | 1 |
| Choi, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for metformin and Rectal Neoplasms
| Article | Year |
|---|---|
Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis.
Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Humans; Metformin; Neoadjuvant Therapy; Rec | 2022 |
Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.
Topics: Chemoradiotherapy; Humans; Metformin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Stag | 2023 |
Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
Topics: Chemoradiotherapy; Diabetes Mellitus; Humans; Metformin; Neoadjuvant Therapy; Rectal Neoplasms; Trea | 2023 |
Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature.
Topics: Animals; Autoantibodies; Bees; Carcinoma, Ovarian Epithelial; Cell Proliferation; Female; Homeostasi | 2021 |
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.
Topics: Aspirin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; H | 2017 |
Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer.
Topics: Antineoplastic Agents; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Colonic Neoplasms; Humans; Imm | 2018 |
13 other studies available for metformin and Rectal Neoplasms
| Article | Year |
|---|---|
Neoadjuvant therapy of metformin is associated with good tumor response after preoperative concurrent chemoradiotherapy for rectal cancer.
Topics: Chemoradiotherapy; Diabetes Mellitus; Humans; Metformin; Neoadjuvant Therapy; Neoplasm Staging; Rect | 2022 |
Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model.
Topics: Animals; CD8-Positive T-Lymphocytes; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Rectal Ne | 2022 |
The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
Topics: Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agen | 2022 |
Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Topics: Animals; Case-Control Studies; Chemoradiotherapy; Combined Modality Therapy; Female; Fluorouracil; H | 2020 |
Metformin Use in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation: The New Magic Bullet?
Topics: Chemoradiotherapy; Humans; Metformin; Neoadjuvant Therapy; Rectal Neoplasms | 2020 |
Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer.
Topics: Adult; Aged; Case-Control Studies; Chemoradiotherapy; Diabetes Mellitus; Disease-Free Survival; Fema | 2020 |
Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?
Topics: Chemoradiotherapy; Humans; Metformin; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Retro | 2021 |
Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Diabetes Mellitus; Female; Follow-Up Studies; | 2019 |
Long term survival in 200 patients with advanced stage of colorectal carcinoma and diabetes mellitus - a single institution experience.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus; Elective Surgical Procedures; Fe | 2019 |
Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Metformin use and improved response to therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Diabetes Mellitus, Type | 2013 |
Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer.
Topics: Aged; Case-Control Studies; Chemoradiotherapy; Diabetes Complications; Female; Humans; Hypoglycemic | 2016 |
Association between Metformin Use and Survival in Nonmetastatic Rectal Cancer Treated with a Curative Resection: A Nationwide Population Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diabet | 2017 |